Accéder directement au contenu

Clément Sire

5
Documents
Identifiants chercheurs

Présentation

After a Ph.D. on the electronic properties and the stability of quasicrystals (1990; ENS Paris & Univ. P. & M. Curie), I spent two years at the AT&T Bell Labs (NJ, USA). There, I worked on high-Tc superconductivity but also started working on nonequilibrium statistic physics, which has since become my main domain of research: stochastic processes and their physical applications, phase separation and coarsening systems, physics of society, and behavioral biology...

Publications

1100561

Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

J. Bourhis , Y. Tao , X. Sun , C. Sire , L. Martin
Annals of Oncology, 2021, 32 (5), pp.S1310. ⟨10.1016/j.annonc.2021.08.2112⟩
Article dans une revue hal-03600467v1

3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck

J. Bourhis , X. Sun , C. Le Tourneau , Y. Pointreau , C. Sire
Annals of Oncology, 2020, 31 (4), pp.S1168. ⟨10.1016/j.annonc.2020.08.2269⟩
Article dans une revue hal-03600472v1

Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 ``PembroRad'' randomized trial

J. Bourhis , C. Sire , Y. Tao , L. Martin , M. Alfonsi
Annals of Oncology, 2020, 31 (4), pp.S1168. ⟨10.1016/j.annonc.2020.08.2268⟩
Article dans une revue hal-03600471v1

Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH)

Y. Tao , A. Auperin , X. Sun , C. Sire , L. Martin
Annals of Oncology, 2019, 30 (5), pp.454
Article dans une revue hal-03600474v1

Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

J. Bourhis , X. Sun , Y. Pointreau , C. Sire , C. Le Tourneau
Annals of Oncology, 2019, 30 (5), pp.902
Article dans une revue hal-03600473v1